{"success":true,"data":{"pressRelease":{"id":"147720","rtpr_id":"nGNX7zLqKB-20260918","ticker":"BBIO","exchange":"NASDAQ","all_tickers":["BBIO"],"title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-09-18T20:01:00.104Z","article_body":"PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.\n(Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical\ncompany focused on developing medicines for genetic conditions, today\nannounced that on September 18, 2026, the compensation committee of\nBridgeBio’s board of directors approved equity grants to 36 new employees in\nrestricted stock units for an aggregate of 63,009 shares of the Company’s\ncommon stock. One-fourth of the shares underlying each employee’s restricted\nstock units will vest on November 16, 2027, with one-twelfth of the remaining\nshares underlying each such employee’s restricted stock units vesting on a\nquarterly basis thereafter, in each case, subject to each such employee’s\ncontinued employment with the Company or one of its subsidiaries on such\nvesting dates.\n\nThe above-described awards were each granted as an inducement material to the\nemployees entering into employment with the Company in accordance with Nasdaq\nListing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan.\nThe Plan was adopted by BridgeBio’s board of directors in November 2019, and\namended and restated on February 10, 2023 and on December 13, 2023.\n\nAbout BridgeBio Pharma, Inc.\nBridgeBio exists to develop transformative medicines for genetic conditions.\nMillions of people worldwide living with genetic conditions lack treatment\noptions, often because drug development for small patient populations can be\ncommercially challenging. We aim to bridge the gap between advancements in\ngenetic science and meaningful medicines for underserved patient populations.\nOur decentralized, hub-and-spoke model is designed for speed, precision, and\nscalability. Autonomous and empowered teams focus on individual conditions,\nwhile a central hub provides the clinical, regulatory, and commercial\ncapabilities needed to bring innovation to market. For more information, visit\nbridgebio.com\n(https://www.globenewswire.com/Tracker?data=6MszcoMiU3ACk0f0THX4WkaFQ9NJc1fElk1AVHsKPzerGTer5WDfWkfxqosTtzMKB1a9Ry4_epZqMZMYyz7k7wegJxE8Zgvab52XUSE6rIJWlYc2lzZoDJiIiYrGa3ow93Qie1v0MNxw1LqUgaR9sLdu3Fek64OvXarOdRj8QBRKStnPD8FPBw1nclGKnRi7IGT54q9LqgH4Owtf0lf5FnhbRiH8yZQqwfVJjT2yRdC9xNRUQl-6EBh7GOFDeq11)\nand follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=6k2KSPswT4rW0t9Pz326LGz56HOB66t1DYIa8l2M2mS2fkquIqNQ0zrrY-c4PkJYb6gY5a64Ra0RBOtjfAVczZO3QSry_cfJURw3GtaH912N9w2UYYOiLdtxFE36BqnnSIr-48co3tYhOdS3I6EJj6fW0HBWdcihKRQ5DBCkyQVxFoCypHOniGVCzIWm18ejKiW0J1J4hAxS1lHQkDCSv0VcQR-86W5xKuKtJ6d6FOzy94XjQNwEdPymdE5q4ri5),\nX\n(https://www.globenewswire.com/Tracker?data=8GXNdXhPmGx2jasE9wD7rlOVe8wbNszHSWqxOl6stu1wTiUDkVF6hHR7CHi4KTJI-QwkUkJy8YpiZkfBDnoJThKjr2eE5VFvAVlpe_0VWU9cgSjtI3fwj5zzlp-igzfSp-JnLkSKqwaHpId_TTV71yLbiahrqHi0VdnZx3B2WOSmHXbz3ytuVwFOkjJQNyGw_IR7iPHDk2wrFpqI_Y0Saw==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=Yu5JgytxpC_q3e3ALI_rr-UQrYTvgtengLNzlL7LDTkuQ6dpTIlvm4TTrAgqsi2TcnnxGoBcnNJiA-d7s2dpqrE0dz_A-VUVkgTxFr4WK1o1gjeqyOPqB8qXrXx3YgG-BfhZMEg2xNCLSrk2iphZZ8RgcrDDPFsLg4VO5_rcVLlLg5ML7Of5sCJ5-2s_Wcig-D79FpcQ8f4e_MK1nhJUtRcZIMCSTQJNIayNaeG3LU8z4fYTTM3CjKbVF3GMM3pSaLSQeV3bJj-FO_eZEY85Kg==),\nInstagram\n(https://www.globenewswire.com/Tracker?data=T76-KAlwVW4MgjAe6iyT4U1lJdCFl_7YZhKzuiLzPz9Yk6bGMvxXTbNEyxeiWrgdP0VPuIe4iK_wztoXhDVyLSg57myFfvjchoF_8oKiqufO7WWOxMpZivWvAXti7t_6_b0gH3y-q9igkkR_6tIkbWerdZPMmAKu03kmuid1dZ44PnOFu6OPDY_zagi2za8w16JyvxmuZz7Kny4dtY2gIdO73cS5fSJ-yZQ772cnQMvuXSIqFKMk2WOQ6y4EYrQz),\nYouTube\n(https://www.globenewswire.com/Tracker?data=wyeY_CpXAmXNbOY0wHT-8weYKddLoKgOHdHPWjXl2_dme5POH4iI1UdxfV7Su5IdRMgjk8Yt2dEyOC33ckQ_m2rpZ60SHPPSK7paiccboi3uFX6davTjIOTB1qOUNdgRqS3LEccwTGeQ9yVu6Z5hSPhlmuWq2lv6kakV_ySgT621Nq94ahTRz1fm1jNy9VLsVZgOvM6BXTEES0PkNqznwZIhSNXjqHM76r6acuU-6KpHZhDJza_kjYEqXmxDQL1M),\nand TikTok\n(https://www.globenewswire.com/Tracker?data=ckfHRfOe1PkqlDqoj1zxl5jOcYMbJbaQnEMGmOaD5vbRvYITU3EtS1YdMY5ZYEXBXHW23MQRkUUvvWNAVnxJLP25F3gfZTtPDiPO7hLFG2i3YqUNmvx3Orhjgn0iUmdUwBVr8fPSxr2mPOPpNnR3Wf9RITeYyj37EJdk1ggoiLdlAGhFRmbFbM9Qu6I6LbDVZaeNGIKVLEKGJIBheONwquMoNH-q8OxvID7yFMcvb-xqaja70uao_CICLi4SANmZ).\n\nBridgeBio Media Contact:\nKaitlyn Reilly, Director, Communications\ncontact@bridgebio.com\n(650)-789-8220\n\nBridgeBio Investor Contact:\nKristen Kelleher, Director, Investor Relations\nir@bridgebio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2074ba9b-0e5b-41fa-baac-553f1345bb75)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7zLqKB-20260918","title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"BBIO","created":"2026-09-18T20:01:00.104Z","tickers":["BBIO"],"exchange":"NASDAQ","article_body":"PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.\n(Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical\ncompany focused on developing medicines for genetic conditions, today\nannounced that on September 18, 2026, the compensation committee of\nBridgeBio’s board of directors approved equity grants to 36 new employees in\nrestricted stock units for an aggregate of 63,009 shares of the Company’s\ncommon stock. One-fourth of the shares underlying each employee’s restricted\nstock units will vest on November 16, 2027, with one-twelfth of the remaining\nshares underlying each such employee’s restricted stock units vesting on a\nquarterly basis thereafter, in each case, subject to each such employee’s\ncontinued employment with the Company or one of its subsidiaries on such\nvesting dates.\n\nThe above-described awards were each granted as an inducement material to the\nemployees entering into employment with the Company in accordance with Nasdaq\nListing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan.\nThe Plan was adopted by BridgeBio’s board of directors in November 2019, and\namended and restated on February 10, 2023 and on December 13, 2023.\n\nAbout BridgeBio Pharma, Inc.\nBridgeBio exists to develop transformative medicines for genetic conditions.\nMillions of people worldwide living with genetic conditions lack treatment\noptions, often because drug development for small patient populations can be\ncommercially challenging. We aim to bridge the gap between advancements in\ngenetic science and meaningful medicines for underserved patient populations.\nOur decentralized, hub-and-spoke model is designed for speed, precision, and\nscalability. Autonomous and empowered teams focus on individual conditions,\nwhile a central hub provides the clinical, regulatory, and commercial\ncapabilities needed to bring innovation to market. For more information, visit\nbridgebio.com\n(https://www.globenewswire.com/Tracker?data=6MszcoMiU3ACk0f0THX4WkaFQ9NJc1fElk1AVHsKPzerGTer5WDfWkfxqosTtzMKB1a9Ry4_epZqMZMYyz7k7wegJxE8Zgvab52XUSE6rIJWlYc2lzZoDJiIiYrGa3ow93Qie1v0MNxw1LqUgaR9sLdu3Fek64OvXarOdRj8QBRKStnPD8FPBw1nclGKnRi7IGT54q9LqgH4Owtf0lf5FnhbRiH8yZQqwfVJjT2yRdC9xNRUQl-6EBh7GOFDeq11)\nand follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=6k2KSPswT4rW0t9Pz326LGz56HOB66t1DYIa8l2M2mS2fkquIqNQ0zrrY-c4PkJYb6gY5a64Ra0RBOtjfAVczZO3QSry_cfJURw3GtaH912N9w2UYYOiLdtxFE36BqnnSIr-48co3tYhOdS3I6EJj6fW0HBWdcihKRQ5DBCkyQVxFoCypHOniGVCzIWm18ejKiW0J1J4hAxS1lHQkDCSv0VcQR-86W5xKuKtJ6d6FOzy94XjQNwEdPymdE5q4ri5),\nX\n(https://www.globenewswire.com/Tracker?data=8GXNdXhPmGx2jasE9wD7rlOVe8wbNszHSWqxOl6stu1wTiUDkVF6hHR7CHi4KTJI-QwkUkJy8YpiZkfBDnoJThKjr2eE5VFvAVlpe_0VWU9cgSjtI3fwj5zzlp-igzfSp-JnLkSKqwaHpId_TTV71yLbiahrqHi0VdnZx3B2WOSmHXbz3ytuVwFOkjJQNyGw_IR7iPHDk2wrFpqI_Y0Saw==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=Yu5JgytxpC_q3e3ALI_rr-UQrYTvgtengLNzlL7LDTkuQ6dpTIlvm4TTrAgqsi2TcnnxGoBcnNJiA-d7s2dpqrE0dz_A-VUVkgTxFr4WK1o1gjeqyOPqB8qXrXx3YgG-BfhZMEg2xNCLSrk2iphZZ8RgcrDDPFsLg4VO5_rcVLlLg5ML7Of5sCJ5-2s_Wcig-D79FpcQ8f4e_MK1nhJUtRcZIMCSTQJNIayNaeG3LU8z4fYTTM3CjKbVF3GMM3pSaLSQeV3bJj-FO_eZEY85Kg==),\nInstagram\n(https://www.globenewswire.com/Tracker?data=T76-KAlwVW4MgjAe6iyT4U1lJdCFl_7YZhKzuiLzPz9Yk6bGMvxXTbNEyxeiWrgdP0VPuIe4iK_wztoXhDVyLSg57myFfvjchoF_8oKiqufO7WWOxMpZivWvAXti7t_6_b0gH3y-q9igkkR_6tIkbWerdZPMmAKu03kmuid1dZ44PnOFu6OPDY_zagi2za8w16JyvxmuZz7Kny4dtY2gIdO73cS5fSJ-yZQ772cnQMvuXSIqFKMk2WOQ6y4EYrQz),\nYouTube\n(https://www.globenewswire.com/Tracker?data=wyeY_CpXAmXNbOY0wHT-8weYKddLoKgOHdHPWjXl2_dme5POH4iI1UdxfV7Su5IdRMgjk8Yt2dEyOC33ckQ_m2rpZ60SHPPSK7paiccboi3uFX6davTjIOTB1qOUNdgRqS3LEccwTGeQ9yVu6Z5hSPhlmuWq2lv6kakV_ySgT621Nq94ahTRz1fm1jNy9VLsVZgOvM6BXTEES0PkNqznwZIhSNXjqHM76r6acuU-6KpHZhDJza_kjYEqXmxDQL1M),\nand TikTok\n(https://www.globenewswire.com/Tracker?data=ckfHRfOe1PkqlDqoj1zxl5jOcYMbJbaQnEMGmOaD5vbRvYITU3EtS1YdMY5ZYEXBXHW23MQRkUUvvWNAVnxJLP25F3gfZTtPDiPO7hLFG2i3YqUNmvx3Orhjgn0iUmdUwBVr8fPSxr2mPOPpNnR3Wf9RITeYyj37EJdk1ggoiLdlAGhFRmbFbM9Qu6I6LbDVZaeNGIKVLEKGJIBheONwquMoNH-q8OxvID7yFMcvb-xqaja70uao_CICLi4SANmZ).\n\nBridgeBio Media Contact:\nKaitlyn Reilly, Director, Communications\ncontact@bridgebio.com\n(650)-789-8220\n\nBridgeBio Investor Contact:\nKristen Kelleher, Director, Investor Relations\nir@bridgebio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2074ba9b-0e5b-41fa-baac-553f1345bb75)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-18T20:01:00.14087738Z","server_sent_at_ms":1789761660140},"received_at":"2026-09-18T20:01:00.195Z","source_url":null},"analysis":{"id":"136521","press_release_id":"147720","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"BridgeBio Pharma's compensation committee approved inducement grants of restricted stock units covering an aggregate of 63,009 shares to 36 new employees on September 18, 2026.\n\nThe awards were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment, with one-fourth of each employee's RSUs vesting on November 16, 2027 and the remainder vesting quarterly thereafter, subject to continued employment.\n\nThis is a routine equity-compensation disclosure tied to hiring; the share count is immaterial relative to shares outstanding and contains no new financial or pipeline information.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement-grant boilerplate -- suppress."},"keyFigures":{"customDimensions":{"new_employee_count":36,"rsu_shares_granted":63009}},"namedEntities":{"people":[{"name":"Kaitlyn Reilly","role":"Director, Communications"},{"name":"Kristen Kelleher","role":"Director, Investor Relations"}],"products":[],"companies":[{"name":"BridgeBio Pharma, Inc.","ticker":"BBIO","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine Nasdaq 5635(c)(4) inducement-grant disclosure covering just 63,009 RSU shares for 36 new hires. Boilerplate equity-compensation news with no financial, clinical, or strategic content."},"tickerRelevance":{"others":[],"primary":"BBIO"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"routine-equity-compensation","issuerAuthored":true,"householdBrandBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"BridgeBio Pharma's compensation committee approved inducement grants of restricted stock units covering an aggregate of 63,009 shares to 36 new employees on September 18, 2026.\n\nThe awards were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment, with one-fourth of each employee's RSUs vesting on November 16, 2027 and the remainder vesting quarterly thereafter, subject to continued employment.\n\nThis is a routine equity-compensation disclosure tied to hiring; the share count is immaterial relative to shares outstanding and contains no new financial or pipeline information.","key_figures":{"customDimensions":{"new_employee_count":36,"rsu_shares_granted":63009}},"named_entities":{"people":[{"name":"Kaitlyn Reilly","role":"Director, Communications"},{"name":"Kristen Kelleher","role":"Director, Investor Relations"}],"products":[],"companies":[{"name":"BridgeBio Pharma, Inc.","ticker":"BBIO","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-18T20:01:12.823Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"routine-equity-compensation","issuerAuthored":true,"householdBrandBoost":false}},"durationMs":12621,"modelName":"glm-5.3-flash"}}